Song Xinyu, Chen Dawei, Guo Jun, Kong Li, Wang Haiyong, Wang Zhehai
Department of Medical Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, People's Republic of China,
School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong, People's Republic of China.
Onco Targets Ther. 2018 Nov 27;11:8421-8426. doi: 10.2147/OTT.S184030. eCollection 2018.
Several clinical trials have reported that intrapleural infusion of bevacizumab with or without cisplatin exhibits encouraging efficacy in nonsquamous non-small cell lung cancer (NS-NSCLC) patients with malignant serous cavity effusion. However, most of the studies included a number of different types of cancers or different hydrops types rather than focusing on one. In addition, no study reported the efficacy and toxicity of intrapleural infusion of bevacizumab and pemetrexed for advanced NS-NSCLC patients with malignant pleural effusion (MPE).
We retrospectively collected patients with MPE mediated from NS-NSCLC who underwent intrapleural infusion of bevacizumab between August 2012 and February 2017. According to the different combined agents with bevacizumab, we divide patients into two groups: Group 1 (BP Group) intrapleural infusion of bevacizumab combined with pemetrexed and Group 2 (BD group) intrapleural infusion of bevacizumab combined with cisplatin.
A total of 45 patients were enrolled in this study. Twenty-two of them received intrapleuralinfusion of bevacizumab and pemetrexed every 2 weeks, 23 received bevacizumab and cisplatin after draining effusion as much as possible. The progression-free survival for patients in BP group was significantly higher than BD group ( < 0.05) while the overall survival between the two groups was not significantly different ( > 0.05). In addition, there was no statistical difference in adverse effects between two groups.
Intrapleural infusion of bevacizumab and pemetrexed is effective and tolerable for patients with MPE mediated from NSCLC.
多项临床试验报告称，在伴有恶性浆膜腔积液的非鳞状非小细胞肺癌（NS-NSCLC）患者中，胸腔内注射贝伐单抗联合或不联合顺铂显示出令人鼓舞的疗效。然而，大多数研究纳入了多种不同类型的癌症或不同类型的积液，而非专注于某一种。此外，尚无研究报道胸腔内注射贝伐单抗和培美曲塞对晚期NS-NSCLC伴恶性胸腔积液（MPE）患者的疗效和毒性。
我们回顾性收集了2012年8月至2017年2月期间接受胸腔内注射贝伐单抗治疗的由NS-NSCLC介导的MPE患者。根据与贝伐单抗联合使用的不同药物，我们将患者分为两组：第1组（BP组）胸腔内注射贝伐单抗联合培美曲塞，第2组（BD组）胸腔内注射贝伐单抗联合顺铂。
本研究共纳入45例患者。其中22例每2周接受一次胸腔内注射贝伐单抗和培美曲塞，23例在尽可能排净积液后接受贝伐单抗和顺铂治疗。BP组患者的无进展生存期显著高于BD组（<0.05），而两组间的总生存期无显著差异（>0.05）。此外，两组间不良反应无统计学差异。
胸腔内注射贝伐单抗和培美曲塞对NSCLC介导的MPE患者有效且耐受性良好。
